( MENAFN - ACCESSWIRE) iDose TR helps patients with glaucoma take long-term control of high eye pressure. WILMINGTON, NC / ACCESSWIRE / May 28, 2024 / Wilmington Eye is proud to announce the availability of iDose® TR (travoprost intraocular implant) 75 mcg. iDose TR is a new, FDA approved treatment that is designed to provide long duration, continuous drug therapy directly inside the eye, helping patients take better control over the elevated eye pressure associated with open-angle glaucoma or ocular hypertension.
Glaucoma is an eye disease caused by increased eye pressure and can also damage the optic nerve, which carries visual information from the eyes to the brain. If left untreated, glaucoma can cause permanent damage to the eye, which means vision loss cannot be reversed. Prescription eye drops are the most common treatment for glaucoma, but they can be difficult to administer correctly and can cause uncomfortable or irritating side effects for most patients.
High rates of non-compliance and non-adherence to prescription medications contribute to disease progression. "With iDose TR, we confront the standard practice of relying on topical drops, which may cause unpleasant side effects and be challenging to properly administer multiple times a day," said Dr. Robert van der Vaart, partner and board-certified ophthalmic surgeon at Wilmington Eye.
"By delivering an effective therapy directly inside of the eye, iDose TR is an alternative to prescription eye drops and a hands.
